vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and VALVOLINE INC (VVV). Click either name above to swap in a different company.
VALVOLINE INC is the larger business by last-quarter revenue ($461.8M vs $281.3M, roughly 1.6× Guardant Health, Inc.). VALVOLINE INC runs the higher net margin — -7.1% vs -45.7%, a 38.6% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 11.5%). VALVOLINE INC produced more free cash flow last quarter ($7.4M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 9.0%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Valvoline Inc. is an American retail automotive services company based in Lexington, Kentucky. It licenses the name for a number of Valvoline-labeled automotive oil, additives, and lubricants. It also owns the Valvoline Instant Oil Change, Great Canadian Oil Change and Valvoline Express Care car repair chains. As of 2023, it is the second largest oil change service provider in the United States with 10% market share and over 1,650 locations.
GH vs VVV — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $461.8M |
| Net Profit | $-128.5M | $-32.8M |
| Gross Margin | 64.6% | 37.4% |
| Operating Margin | -43.0% | 4.0% |
| Net Margin | -45.7% | -7.1% |
| Revenue YoY | 39.4% | 11.5% |
| Net Profit YoY | -15.8% | -135.8% |
| EPS (diluted) | $-1.01 | $-0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $461.8M | ||
| Q3 25 | $265.2M | $453.8M | ||
| Q2 25 | $232.1M | $439.0M | ||
| Q1 25 | $203.5M | $403.2M | ||
| Q4 24 | $201.8M | $414.3M | ||
| Q3 24 | $191.5M | $435.5M | ||
| Q2 24 | $177.2M | $421.4M | ||
| Q1 24 | $168.5M | $388.7M |
| Q4 25 | $-128.5M | $-32.8M | ||
| Q3 25 | $-92.7M | $25.0M | ||
| Q2 25 | $-99.9M | $56.5M | ||
| Q1 25 | $-95.2M | $37.6M | ||
| Q4 24 | $-111.0M | $91.6M | ||
| Q3 24 | $-107.8M | $92.3M | ||
| Q2 24 | $-102.6M | $45.9M | ||
| Q1 24 | $-115.0M | $41.4M |
| Q4 25 | 64.6% | 37.4% | ||
| Q3 25 | 64.7% | 39.1% | ||
| Q2 25 | 65.0% | 40.5% | ||
| Q1 25 | 63.3% | 37.3% | ||
| Q4 24 | 61.6% | 36.9% | ||
| Q3 24 | 61.1% | 39.1% | ||
| Q2 24 | 59.1% | 39.7% | ||
| Q1 24 | 61.2% | 37.6% |
| Q4 25 | -43.0% | 4.0% | ||
| Q3 25 | -37.3% | 18.6% | ||
| Q2 25 | -45.9% | 21.6% | ||
| Q1 25 | -54.6% | 16.6% | ||
| Q4 24 | -62.4% | 34.7% | ||
| Q3 24 | -61.3% | 30.9% | ||
| Q2 24 | -56.8% | 22.2% | ||
| Q1 24 | -59.2% | 19.7% |
| Q4 25 | -45.7% | -7.1% | ||
| Q3 25 | -35.0% | 5.5% | ||
| Q2 25 | -43.0% | 12.9% | ||
| Q1 25 | -46.8% | 9.3% | ||
| Q4 24 | -55.0% | 22.1% | ||
| Q3 24 | -56.3% | 21.2% | ||
| Q2 24 | -57.9% | 10.9% | ||
| Q1 24 | -68.2% | 10.7% |
| Q4 25 | $-1.01 | $-0.26 | ||
| Q3 25 | $-0.74 | $0.20 | ||
| Q2 25 | $-0.80 | $0.44 | ||
| Q1 25 | $-0.77 | $0.29 | ||
| Q4 24 | $-0.90 | $0.71 | ||
| Q3 24 | $-0.88 | $0.70 | ||
| Q2 24 | $-0.84 | $0.35 | ||
| Q1 24 | $-0.94 | $0.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $69.9M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $307.6M |
| Total Assets | $2.0B | $3.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $69.9M | ||
| Q3 25 | $580.0M | $51.6M | ||
| Q2 25 | $629.1M | $68.3M | ||
| Q1 25 | $698.6M | $61.9M | ||
| Q4 24 | $525.5M | $60.0M | ||
| Q3 24 | $585.0M | $68.3M | ||
| Q2 24 | $933.7M | $65.7M | ||
| Q1 24 | $1.0B | $494.5M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $307.6M | ||
| Q3 25 | $-354.5M | $338.5M | ||
| Q2 25 | $-305.5M | $313.6M | ||
| Q1 25 | $-250.8M | $248.7M | ||
| Q4 24 | $-139.6M | $229.8M | ||
| Q3 24 | $-60.1M | $185.6M | ||
| Q2 24 | $-1.6M | $106.5M | ||
| Q1 24 | $68.3M | $60.1M |
| Q4 25 | $2.0B | $3.4B | ||
| Q3 25 | $1.3B | $2.7B | ||
| Q2 25 | $1.3B | $2.6B | ||
| Q1 25 | $1.3B | $2.5B | ||
| Q4 24 | $1.5B | $2.3B | ||
| Q3 24 | $1.5B | $2.4B | ||
| Q2 24 | $1.6B | $2.4B | ||
| Q1 24 | $1.7B | $2.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $64.8M |
| Free Cash FlowOCF − Capex | $-54.2M | $7.4M |
| FCF MarginFCF / Revenue | -19.3% | 1.6% |
| Capex IntensityCapex / Revenue | 9.9% | 12.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $57.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $64.8M | ||
| Q3 25 | $-35.4M | $121.9M | ||
| Q2 25 | $-60.3M | $86.9M | ||
| Q1 25 | $-62.7M | $47.2M | ||
| Q4 24 | $-64.5M | $41.2M | ||
| Q3 24 | $-51.1M | $101.3M | ||
| Q2 24 | $-94.0M | $75.6M | ||
| Q1 24 | $-30.3M | $68.3M |
| Q4 25 | $-54.2M | $7.4M | ||
| Q3 25 | $-45.8M | $23.0M | ||
| Q2 25 | $-65.9M | $32.0M | ||
| Q1 25 | $-67.1M | $-4.6M | ||
| Q4 24 | $-83.4M | $-12.4M | ||
| Q3 24 | $-55.3M | $29.9M | ||
| Q2 24 | $-99.1M | $9.8M | ||
| Q1 24 | $-37.2M | $23.4M |
| Q4 25 | -19.3% | 1.6% | ||
| Q3 25 | -17.3% | 5.1% | ||
| Q2 25 | -28.4% | 7.3% | ||
| Q1 25 | -33.0% | -1.1% | ||
| Q4 24 | -41.3% | -3.0% | ||
| Q3 24 | -28.9% | 6.9% | ||
| Q2 24 | -55.9% | 2.3% | ||
| Q1 24 | -22.1% | 6.0% |
| Q4 25 | 9.9% | 12.4% | ||
| Q3 25 | 3.9% | 21.8% | ||
| Q2 25 | 2.4% | 12.5% | ||
| Q1 25 | 2.2% | 12.8% | ||
| Q4 24 | 9.4% | 12.9% | ||
| Q3 24 | 2.2% | 16.4% | ||
| Q2 24 | 2.9% | 15.6% | ||
| Q1 24 | 4.1% | 11.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | 4.88× | ||
| Q2 25 | — | 1.54× | ||
| Q1 25 | — | 1.26× | ||
| Q4 24 | — | 0.45× | ||
| Q3 24 | — | 1.10× | ||
| Q2 24 | — | 1.65× | ||
| Q1 24 | — | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
VVV
| Oil Change And Related Fees | $337.7M | 73% |
| Non Oil Change And Related Fees | $100.5M | 22% |
| Franchise Fees And Other | $23.6M | 5% |
